- ST Pharm has signed an API supply agreement worth 89.7 billion won ($59.8 million) with a European pharmaceutical company.
ST Pharm has signed an agreement valued at approximately 89.7 billion won ($59.8 million) to supply active pharmaceutical ingredients (APIs) for oligonucleotide therapeutics to a European pharmaceutical company. The client and product name were not disclosed due to confidentiality clauses.
The contract is the largest single API agreement for oligonucleotides reported by the company and represents about 27% of its 2025 revenue of 331.5 billion won. The APIs will be used in a therapeutic agent that has already been commercialized globally, with supply expected to support markets including Europe.
The delivery period for the agreement runs from the contract start date through November 17, 2027. The deal reflects ongoing demand for oligonucleotide-based therapies and associated manufacturing capacity.
ST Pharm operates in the CDMO and contract manufacturing space, supporting API production across clinical and commercial stages. The company stated that its experience spans projects from early-stage clinical volumes to commercial-scale production.
An ST Pharm official said, “Our experience in executing projects that span from early-stage clinical volumes to commercial-scale production is a unique competitive advantage that is difficult to build in a short period.”
